ZA200108130B - Treatment of pulmonary hypertension. - Google Patents

Treatment of pulmonary hypertension.

Info

Publication number
ZA200108130B
ZA200108130B ZA200108130A ZA200108130A ZA200108130B ZA 200108130 B ZA200108130 B ZA 200108130B ZA 200108130 A ZA200108130 A ZA 200108130A ZA 200108130 A ZA200108130 A ZA 200108130A ZA 200108130 B ZA200108130 B ZA 200108130B
Authority
ZA
South Africa
Prior art keywords
pulmonary hypertension
treatment
preparation
pharmaceutical composition
treating pulmonary
Prior art date
Application number
ZA200108130A
Other languages
English (en)
Inventor
Maha Ghazzi
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA200108130B publication Critical patent/ZA200108130B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200108130A 2000-10-04 2001-10-03 Treatment of pulmonary hypertension. ZA200108130B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23753800P 2000-10-04 2000-10-04

Publications (1)

Publication Number Publication Date
ZA200108130B true ZA200108130B (en) 2002-06-06

Family

ID=22894157

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108130A ZA200108130B (en) 2000-10-04 2001-10-03 Treatment of pulmonary hypertension.

Country Status (13)

Country Link
US (1) US6740648B2 (ko)
EP (1) EP1195166B1 (ko)
JP (1) JP3838065B2 (ko)
KR (1) KR100445946B1 (ko)
AT (1) ATE367815T1 (ko)
CA (1) CA2357833C (ko)
DE (1) DE60129518T2 (ko)
ES (1) ES2288899T3 (ko)
HU (1) HUP0104085A3 (ko)
IL (1) IL145684A (ko)
MY (1) MY136383A (ko)
NZ (1) NZ514542A (ko)
ZA (1) ZA200108130B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US8532938B2 (en) 2005-11-17 2013-09-10 The Invention Science Fund I, Llc Testing-dependent administration of a nutraceutical
US20070112796A1 (en) 2005-11-17 2007-05-17 Jung Edward K Research in providing assistance related to health
US20070112592A1 (en) 2005-11-17 2007-05-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Payments in providing assistance related to health
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) * 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
US20130288370A1 (en) 2010-10-15 2013-10-31 Cytopherx, Inc. Cytopheresis cartridges and use thereof
AU2012364760B2 (en) 2012-01-09 2018-05-31 Seastar Medical Inc. Cartridge and method for increasing myocardial function
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
WO2015171989A1 (en) * 2014-05-08 2015-11-12 University Of Maryland, Baltimore Methods for assessing differential risk for developing heart failure
WO2015193889A1 (en) * 2014-06-18 2015-12-23 Sonivie Ltd. Method for treating secondary pulmonary hypertension
CN110237077A (zh) * 2019-05-10 2019-09-17 辽宁大学 考尼伐坦在制备降血脂药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225402A (en) 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5338755A (en) 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
PL177738B1 (pl) * 1993-07-21 2000-01-31 Yamanouchi Pharma Co Ltd Pochodna benzazepiny skondensowanej z 5-członowym pierścieniem aromatycznym zawierającym azot oraz kompozycja farmaceutyczna zawierająca taką pochodną
NZ271454A (en) 1993-08-26 1997-07-27 Yamanouchi Pharma Co Ltd Difluoro substituted benzazepine derivatives and pharmaceutical compositions
JP2649610B2 (ja) 1993-11-10 1997-09-03 日本たばこ産業株式会社 クロマン誘導体及びその医薬用途
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
KR20010034461A (ko) * 1998-01-28 2001-04-25 요시다 쇼지 시기능 장해의 예방 또는 치료제
HU229074B1 (en) * 1999-01-19 2013-07-29 Ortho Mcneil Pharm Inc Tricyclic benzodiazepines as vasopressin receptor antagonists
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck

Also Published As

Publication number Publication date
HU0104085D0 (en) 2001-12-28
NZ514542A (en) 2002-10-25
ATE367815T1 (de) 2007-08-15
JP3838065B2 (ja) 2006-10-25
MY136383A (en) 2008-09-30
HUP0104085A2 (hu) 2002-07-29
DE60129518T2 (de) 2008-03-20
CA2357833A1 (en) 2002-04-04
EP1195166A2 (en) 2002-04-10
DE60129518D1 (de) 2007-09-06
HUP0104085A3 (en) 2004-11-29
US6740648B2 (en) 2004-05-25
EP1195166B1 (en) 2007-07-25
IL145684A (en) 2007-06-17
KR20020027237A (ko) 2002-04-13
EP1195166A3 (en) 2003-12-03
US20020128259A1 (en) 2002-09-12
ES2288899T3 (es) 2008-02-01
JP2002128696A (ja) 2002-05-09
CA2357833C (en) 2005-11-15
IL145684A0 (en) 2002-06-30
KR100445946B1 (ko) 2004-08-25

Similar Documents

Publication Publication Date Title
IL145684A0 (en) Treatment of pulmonary hypertension
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
HK1067129A1 (en) A process for the preparation of perindopril, its analgous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
GB0111523D0 (en) Chemical compounds
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
HUP0004211A3 (en) Use of pde-5 inhibitors for the preparation of pharmaceutical compositions treating pulmonary hypertension
MXPA03008853A (es) Antagonistas de ccr5 utiles para el tratamiento del sida.
PL350167A1 (en) Medicament for treating hypertension
MXPA03002909A (es) Compuestos quimicos.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
AU7287201A (en) Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro-2-naphthyl)-4-morpholinobenzamide
ZA200500431B (en) Medicinal composition for treating arteriosclerosis
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
PT1434588E (pt) Derivados de ácido [[-(amino-3,4-dioxo-1-ciclobuteno-1- il)amino]alquil] para o tratamento da dor
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
IL155706A0 (en) Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
HUP0400495A3 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
NZ516209A (en) Indoloazepines as vasopressin receptor antagonists
ZA200000313B (en) Neuropeptide Y antagonists.
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.